Loading...
XNASNOTV
Market cap143mUSD
Dec 24, Last price  
4.47USD
1D
13.45%
1Q
202.03%
Jan 2017
480.53%
Name

Bioanalytical Systems Inc

Chart & Performance

D1W1MN
XNAS:NOTV chart
P/E
P/S
0.29
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
20.06%
Rev. gr., 5y
62.27%
Revenues
491m
-14.27%
42,395,04643,047,67545,245,00041,697,00031,784,00028,781,00033,144,00028,208,00022,068,00024,584,00022,698,00020,441,00024,242,00026,346,00043,616,00060,469,00089,605,000547,656,000572,425,000490,739,000
Net income
-108m
L+3.14%
-100,998-2,609,942926,000-1,489,000-5,463,000-2,691,000543,000-6,390,000773,000-1,070,0001,089,000-3,230,000884,000-194,000-790,000-4,685,00010,895,000-337,262,000-105,140,000-108,445,000
CFO
-7m
L
-541,2503,843,9292,928,000598,0002,587,0002,441,0001,088,000-200,0001,519,0001,684,0002,031,0001,060,0001,236,0003,487,0001,777,0001,290,00010,746,000-5,217,00027,883,000-6,805,000
Earnings
Feb 05, 2025

Profile

Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
IPO date
Nov 25, 1997
Employees
2,099
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑092023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑092015‑09
Income
Revenues
490,739
-14.27%
572,425
4.52%
547,656
511.19%
Cost of revenue
477,485
534,300
489,530
Unusual Expense (Income)
NOPBT
13,254
38,125
58,126
NOPBT Margin
2.70%
6.66%
10.61%
Operating Taxes
(21,875)
(19,340)
(15,187)
Tax Rate
NOPAT
35,129
57,465
73,313
Net income
(108,445)
3.14%
(105,140)
-68.83%
(337,262)
-3,195.57%
Dividends
Dividend yield
Proceeds from repurchase of equity
110
118
BB yield
-0.14%
-0.03%
Debt
Debt current
15,312
18,232
30,961
Long-term debt
11,774
439,305
388,367
Deferred revenue
Other long-term liabilities
464,774
6,373
6,477
Net debt
5,654
418,364
400,813
Cash flow
Cash from operating activities
(6,805)
27,883
(5,217)
CAPEX
(22,310)
(27,503)
(36,300)
Cash from investing activities
(16,832)
(28,755)
(333,722)
Cash from financing activities
9,675
15,872
203,151
FCF
53,855
23,900
(135,605)
Balance
Cash
21,432
35,492
18,515
Long term investments
3,681
Excess cash
10,552
Stockholders' equity
(390,247)
(447,206)
(348,021)
Invested Capital
1,040,837
1,139,710
1,099,556
ROIC
3.22%
5.13%
10.58%
ROCE
1.96%
5.13%
7.02%
EV
Common stock shares outstanding
25,897
25,641
24,354
Price
1.70
-44.81%
3.08
-81.72%
16.85
-42.37%
Market cap
44,025
-44.25%
78,974
-80.76%
410,365
1.22%
EV
220,183
496,674
810,572
EBITDA
70,372
92,842
107,450
EV/EBITDA
3.13
5.35
7.54
Interest
46,884
43,019
29,704
Interest/NOPBT
353.73%
112.84%
51.10%